Berenberg Bank set a €124.00 ($147.62) price objective on Bayer (FRA:BAYN) in a research note issued to investors on Tuesday. The brokerage currently has a neutral rating on the healthcare company’s stock.
A number of other research firms also recently issued reports on BAYN. Citigroup set a €130.00 ($154.76) target price on Bayer and gave the company a buy rating in a research report on Thursday, October 5th. UBS set a €125.00 ($148.81) target price on Bayer and gave the company a buy rating in a research report on Monday, November 6th. Deutsche Bank set a €124.00 ($147.62) target price on Bayer and gave the company a buy rating in a research report on Monday, August 28th. Kepler Capital Markets set a €102.00 ($121.43) target price on Bayer and gave the company a neutral rating in a research report on Monday, August 28th. Finally, Sanford C. Bernstein set a €126.00 ($150.00) target price on Bayer and gave the company a buy rating in a research report on Friday, October 6th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the company. Bayer has a consensus rating of Buy and an average price target of €122.19 ($145.46).
Shares of Bayer (FRA BAYN) opened at €105.13 ($125.15) on Tuesday. Bayer has a 12-month low of €90.26 ($107.45) and a 12-month high of €123.82 ($147.40).
TRADEMARK VIOLATION NOTICE: This article was first published by Stock Observer and is owned by of Stock Observer. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.thestockobserver.com/2017/12/08/berenberg-bank-analysts-give-bayer-bayn-a-124-00-price-target.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.